EPIC-NSW Study Response to PBAC Outcome

The EPIC-NSW management team welcomes the release of the Pharmaceutical Benefits Advisory Committee’s decision to recommend the listing of co-formulated tenofovir and emtricitabine for PrEP on the Pharmaceutical Benefits System.

The EPIC-NSW management team will be in touch with each EPIC-NSW clinic in the near future with more details about transitional arrangements.  However, for now, please continue to dispense study medication and enrol new eligible high-risk participants as normal. It is important that EPIC-NSW participants understand that they should continue to take their study PrEP medication as usual.